Samuel Zhang | Chief Business Officer
Innovent Biologics, Inc

Dr. Samuel Zhang is currently Chief Business Officer (CBO) of Innovent Biologicals. Dr. Zhang has over 20 years of industry experience across the entire drug research, development and commercialization spectrum. He has a successful track record in identifying emerging industry trends and promising assets at an early stage, enabling major R&D decisions, and facilitating strategic transactions. Prior to joining Innovent, Dr. Zhang served as CBO at Gracell and NeoImmuneTech and led their global partnership discussions, including the $1.2B Gracell acquisition by AstraZeneca. He has also held positions of increasing responsibility at Eli Lilly, Pfizer, Bristol-Myers Squibb, Novartis, and Merus. Dr. Zhang has a PhD in Molecular Biology from Columbia University, an MBA from the Wharton School of the University of Pennsylvania, and a BS in Biology from Peking University.